7-(3,4-Dichlorophenyl)-5-methyl-6-(1-methylbenzimidazol-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine | 343245-25-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 7-(3,4-Dichlorophenyl)-5-methyl-6-(1-methylbenzimidazol-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine
• 英文别名: 7-(3,4-dichlorophenyl)-5-methyl-6-(1-methylbenzimidazol-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine
• CAS: 343245-25-0
• 化学式: C₂₁H₁₇Cl₂N₅
• 分子量: 410.305
• InChiKey: WKMMAERHZAQFCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  47.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  7-(3,4-Dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5-a]pyrimidine-6-carboxylic acid 、 N-甲基-1,2-苯二胺 在 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 生成 7-(3,4-Dichlorophenyl)-5-methyl-6-(1-methylbenzimidazol-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  Dihydropyrazolopyrimidines containing benzimidazoles as KV1.5 potassium channel antagonists

  摘要：

  Dihydropyrazolopyrimidines with a C6 heterocycle substituent were found to have high potency for block of K(V)1.5. Investigation of the substitution in the benzimidazole ring and the substituent in the 5-position of the dihydropyrazolopyrimidine ring produced 31 a with an IC50 for K(V)1.5 block of 0.030 mu M without significant block of other cardiac ion channels. This compound also showed good bioavailability in rats and robust pharmacodynamic effects in a rabbit model. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.083

文献信息

• Heterocyclic dihydropyrimidine compounds
  申请人：——

  公开号：US20030022890A1

  公开（公告）日：2003-01-30

  Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the K v 1 subfamily of voltage gated K + channels, especially inhibitors K v 1.5 which has been linked to the ultra-rapidly activating delayed rectifier K + current I Kur ), methods of using such compounds in the prevention and treatment of arrhythmia and I Kur -associated conditions, and pharmaceutical compositions containing such compounds.

  本发明涉及一种新型杂环二氢嘧啶化合物，其可作为钾通道功能抑制剂（特别是Kv1亚家族电压门控K+通道的抑制剂，特别是与超快速激活延迟整流K+电流IKur相关的Kv1.5的抑制剂），以及使用这些化合物在预防和治疗心律失常和IKur相关疾病方面的方法，以及含有这些化合物的药物组合物。
• [EN] HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS<br/>[FR] DIHYDROPYRIMIDINES HETEROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DES CANAUX POTASSIUM
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2001040231A1

  公开（公告）日：2001-06-07

  Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors K¿v?1.5 which has been linked to the ultra-rapidly activating delayed rectifier K?+¿ current I¿Kur?), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.

  新型杂环二氢嘧啶化合物可作为钾通道功能抑制剂使用（特别是Kv1亚家族电压门控K+通道的抑制剂，特别是与超快速激活延迟整流K+电流IKur相关的Kv1.5抑制剂），使用这种化合物预防和治疗心律失常和IKur相关疾病的方法，以及含有这种化合物的制药组合物。
• HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP1237891A1

  公开（公告）日：2002-09-11
• US6706720B2
  申请人：——

  公开号：US6706720B2

  公开（公告）日：2004-03-16
• US7157451B2
  申请人：——

  公开号：US7157451B2

  公开（公告）日：2007-01-02